CT waiver is not being considered for Sun Pharma’s pulmonary fixed-dose combination (FDC) product. The CDSCO panel has instructed Sun Pharma to conduct a bioavailability (BA) study for the product. Cookies are used on the website for analytics, advertising, and site improvement. By continuing to use the site, the user agrees to the use of cookies. More information can be found in the Cookie Policy and Cookie Settings.
Source link
CDSCO Panel Tells Sun Pharma on Pulmonary FDC
